Lonza: Selected partner
Lonza is a leading manufacturing company for innovative therapeutics, from small molecules and biologics to cell and gene therapy products. With services to accompany drug manufacturing from discovery down to the production of APIs, Lonza is a highly sought after service partner for customers around the world. Thanks to our collaboration with Lonza, we gain access to innovative technologies for our custom bispecific antibody production services.
Key facts
- Specialization: Biopharmaceutical development and manufacturing solutions
- Technology: Development and manufacturing technologies for products like biologics, small molecules, and CGTs
- Services: support in drug development, manufacturing, and regulatory compliance
- Website: lonza.com
Location
Global Headquarters
Muenchensteinerstrasse 38
Basel, 4002
Switzerland
Global presence
More than 30 sites on 5 continents
About Lonza
Lonza is a global leader in providing integrated solutions to the pharmaceutical, biotech, and specialty ingredients markets. With a focus on advancing clinical and commercial biopharmaceutical production, Lonza offers comprehensive services including non-GMP and GMP manufacturing.
Their innovative bYlok® bispecific antibody technology, for instance, ensures precise heavy-light chain pairing in bsAb production, facilitating high-quality bispecific antibody development.
What is bYlok® bispecific pairing technology?
bYlok® bispecific pairing technology is a bispecific antibody design technology developed by Lonza. It addresses one of the main challenges in bispecific antibody production: the correct pairing of heavy and light chains.
By engineering the bispecific antibody sequence to move a disulfide bridge from the constant region to the variable region, bYlok® technology facilitates precise heavy-light chain pairing. This modification drives more than 95% correct pairing of heavy and light chains, ensuring the production of IgG-like bispecific antibodies with high precision and consistency.
Unlock the full potential of your research with Lonza and evitria
By partnering with Lonza, evitria offers unparalleled expertise in bispecific antibody development. Leveraging Lonza’s bYlok® bispecific pairing technology and evitria’s CHO cell-based transient expression system, our workflow provides consistent, high-quality results tailored to your specific research needs.
This approach can accelerate project timelines and enhance the reliability of outcomes, empowering researchers to achieve significant biopharmaceutical advancements with efficiency and confidence.
Get in touch with our experts now!
Our team of experts is looking forward to talk with you about your plans, concerns and expectations regarding our expression services.
